Size | Price | Stock | Qty |
---|---|---|---|
5mg |
|
||
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
500mg |
|
||
Other Sizes |
|
Purity: ≥98%
Adavivint (formerly known as SM04690) is a novel, potent, specific/selective inhibitor of canonical Wnt signaling pathway with an EC50 of 19.5 nM for inhibiting the TCF/LEF reporter in SW480 colon cancer cells. It is ∼150- to 500-fold more potent than the other known Wnt inhibitors across multiple cellular assays. SM04690 induced hMSC (human mesenchymal stem cells) differentiation into mature, functional chondrocytes and decreased cartilage catabolic marker levels compared to vehicle. A single SM04690 intra-articular (IA) injection was efficacious in a rodent OA model, with increased cartilage thickness, evidence for cartilage regeneration, and protection from cartilage catabolism observed, resulting in significantly improved Osteoarthritis Research Society International (OARSI) histology scores and biomarkers, compared to vehicle. SM04690 induced chondrogenesis and appeared to inhibit joint destruction in a rat OA model, and is a candidate for a potential disease modifying therapy for OA.
ln Vitro |
Adavivint (SM04690) has no effect on the SV40 luciferase reporter and is a strong carboxyl Wnt signaling activator with an EC50 of 19.5 nM as determined by high-field TCF/LEF reporter on SW480 porous media. Human mesenchymal stem cells (hMSC) aggregated at an EC50 of 10 nM. Adavivint (30 nM) shields chondrocytes from further damage [1].
|
---|---|
ln Vivo |
In effective cruciate ligament tear and partial medial meniscectomy osteoarthritis (ACLT + pMMx OA) mice, Adavivint (0.3 μg) improves cartilage healing and protection [1].
|
References |
[1]. Deshmukh V, et al. A small-molecule inhibitor of the Wnt pathway (SM04690) as a potential disease modifying agent for the treatment of osteoarthritis of the knee. Osteoarthritis Cartilage. 2018 Jan;26(1):18-27.
|
Molecular Formula |
C29H24FN7O
|
|
---|---|---|
Molecular Weight |
505.56
|
|
CAS # |
1467093-03-3
|
|
Related CAS # |
1467093-03-3;Adavivint HCl;
|
|
SMILES |
CC(C)CC(=O)Nc1cncc(c1)c2ccc3[nH]nc(c4nc5c(cncc5[nH]4)c6cccc(F)c6)c3c2
|
|
Chemical Name |
|
|
Synonyms |
|
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
|||
---|---|---|---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (4.95 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (4.95 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (4.95 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 1.9780 mL | 9.8900 mL | 19.7800 mL | |
5 mM | 0.3956 mL | 1.9780 mL | 3.9560 mL | |
10 mM | 0.1978 mL | 0.9890 mL | 1.9780 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Osteoarthritis Cartilage.2018 Jan;26(1):18-27. td> |
Osteoarthritis Cartilage.2018 Jan;26(1):18-27. td> |
Osteoarthritis Cartilage.2018 Jan;26(1):18-27. td> |